Chemoinformaics analysis of pyrroloquinazoline Alkaloid.
| Molecular Weight | 168.199 | nRot | 0 |
| Heavy Atom Molecular Weight | 160.135 | nRig | 15 |
| Exact Molecular Weight | 168.069 | nRing | 3 |
| Solubility: LogS | -2.73 | nHRing | 2 |
| Solubility: LogP | 2.289 | No. of Aliphatic Rings | 0 |
| Acid Count | 0 | No. of Aromatic Rings | 3 |
| Base Count | 0 | No. of Aliphatic Carbocycles Rings | 0 |
| Atoms Count | 21 | No. of Aliphatic Hetero Cycles | 0 |
| No. of Heavy Atom | 13 | No. of Aromatic Carbocycles | 1 |
| nHetero | 2 | No. of Aromatic Hetero Cycles | 2 |
| nBridge Head | 0 | No. Saturated Carbocycles | 0 |
| No. of Hydrogen atom | 8 | No. of Saturated Hetero Cycles | 0 |
| No. of Carbon atom | 11 | No. of Saturated Rings | 0 |
| No. of Nitrogen atom | 2 | No. of Arom Atom | 13 |
| No. of Oxygen atom | 0 | No. of Arom Bond | 15 |
| nHA | 1 | APOL | 25.9043 |
| nHD | 1 | BPOL | 9.73566 |
| QED | 0.549 |
| Synth | 2.262 |
| Natural Product Likeliness | -0.399 |
| NR-PPAR-gamma | 0.097 |
| Lipinski | Accepted |
| Pfizer | Accepted |
| GSK | Accepted |
| Golden Triangle | Rejected |
| Pgp-inh | 0.008 |
| Pgp-sub | 0.044 |
| HIA | 0.008 |
| CACO-2 | -4.52 |
| MDCK | 0.0000191 |
| BBB | 0.875 |
| PPB | 0.834104 |
| VDSS | 1.822 |
| FU | 0.175755 |
| CYP1A2-inh | 0.989 |
| CYP1A2-sub | 0.768 |
| CYP2c19-inh | 0.723 |
| CYP2c19-sub | 0.235 |
| CYP2c9-inh | 0.237 |
| CYP2c9-sub | 0.856 |
| CYP2d6-inh | 0.617 |
| CYP2d6-sub | 0.866 |
| CYP3a4-inh | 0.31 |
| CYP3a4-sub | 0.204 |
| CL | 6.04 |
| T12 | 0.62 |
| hERG | 0.032 |
| Ames | 0.772 |
| ROA | 0.938 |
| SkinSen | 0.819 |
| Carcinogencity | 0.319 |
| EI | 0.976 |
| Respiratory | 0.987 |
| NR-Aromatase | 0.899 |
| Antiviral | No |
| Prediction | 0.627229 |